https://scholars.lib.ntu.edu.tw/handle/123456789/549389
標題: | Efficacy of a programmed death-1 checkpoint inhibitor in a case of cutaneous squamous cell carcinoma harboring mutations of TP53 and BRCA2 | 作者: | WEI-LI MA Chou C.-H. JO-PAI CHEN SUNG-HSIN KUO |
公開日期: | 2020 | 出版社: | Blackwell Publishing Inc. | 卷: | 33 | 期: | 6 | 來源出版物: | Dermatologic Therapy | 摘要: | Immune checkpoint blockades were reported to result in clinical responses in inoperable and metastatic cutaneous squamous cell carcinoma (cSCC). This report describes an 87-year-old woman with recurrent cSCC that was initially responsive to cetuximab (the monoclonal antibody against epithelial growth factor receptor) but eventually became refractory to cetuximab and multiple subsequent salvage chemotherapy regimens. Next-generation sequencing of the tumor discovered three single-nucleotide mutations in TP53, copy number amplification in Src, and a heterozygous deletion in BRCA2. Because of the high mutation burden of her neoplasm (35.2 mutations per megabase), we treated her with a programmed death-1 (PD-1) checkpoint inhibitor, pembrolizumab, for 10 months. The tumor regressed 3 months later and complete pathological remission was achieved 10 months after starting treatment. As of writing, the patient has been disease free for 17 months after discontinuing treatment. This is the first reported case of heterozygous deletion of BRCA2 in cSCC. The high mutation burden and BRCA2 mutation might explain why this tumor was highly sensitive to anti-PD-1 treatment. ? 2020 Wiley Periodicals LLC. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85089389044&doi=10.1111%2fdth.14035&partnerID=40&md5=cdf3cba03ad12c3fe2943d5bf60a8cbb https://scholars.lib.ntu.edu.tw/handle/123456789/549389 |
ISSN: | 1396-0296 | DOI: | 10.1111/dth.14035 | SDG/關鍵字: | antihistaminic agent; BRCA2 protein; carboplatin; cetuximab; fluorouracil; paclitaxel; pembrolizumab; protein p53; steroid; vinorelbine tartrate; BRCA2 protein; BRCA2 protein, human; immunological antineoplastic agent; protein p53; TP53 protein, human; adjuvant radiotherapy; aged; Article; cancer chemotherapy; cancer immunotherapy; cancer regression; case report; CD4+ T lymphocyte; CD8+ T lymphocyte; chromosome 13; chromosome 20; clinical article; disease burden; drug efficacy; external auditory canal; female; gene amplification; gene deletion; gene mutation; heterozygosity; high throughput sequencing; human; human tissue; immunohistochemistry; lymph node dissection; lymph node metastasis; lymph vessel metastasis; nuclear magnetic resonance imaging; parotid gland; parotidectomy; pruritus; rash; sentinel lymph node metastasis; single nucleotide polymorphism; skin biopsy; squamous cell skin carcinoma; treatment response; tumor invasion; very elderly; wide excision; genetics; mutation; skin tumor; squamous cell carcinoma; tumor recurrence; Aged, 80 and over; Antineoplastic Agents, Immunological; BRCA2 Protein; Carcinoma, Squamous Cell; Female; Humans; Mutation; Neoplasm Recurrence, Local; Skin Neoplasms; Tumor Suppressor Protein p53 |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。